Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system
- 16 December 2006
- journal article
- research article
- Published by Springer Nature in Surgical Endoscopy
- Vol. 21 (4) , 560-569
- https://doi.org/10.1007/s00464-006-9053-3
Abstract
This study aimed to determine the optimal treatment parameters for the ablation of intestinal metaplasia (IM) containing high-grade dysplasia (HGD) using a balloon-based ablation system for patients undergoing esophagectomy. Immediately before esophagectomy, patients underwent ablation of circumferential segments of the esophagus containing IM-HGD using the HALO360 system. The treatment settings were randomized to 10, 12, or 14 J/cm2 for two, three, or four applications. After esophagectomy, multiple sections from ablation zones were microscopically evaluated. Histologic end points included maximum ablation depth (histologic layer) and complete ablation of all IM-HGD (yes/no). Eight men with a mean age of 57 years (range, 45–71 years) were treated, and 10 treatment zones were created. There were no device-related adverse events. At resection, there was no evidence of a transmural thermal effect. Grossly, ablation zones were clearly demarcated sections of ablated epithelium. The maximum ablation depth was the lamina propria or muscularis mucosae. The highest energy (14 J/cm2, 4 applications) incurred edema in the superficial submucosa, but no submucosa ablation. Complete ablation of IM and HGD occurred in 9 of 10 ablation zones (90%), defined as complete removal of the epithelium with only small foci of “ghost cells” representing nonviable, ablated IM-HGD and demonstrating loss of nuclei and cytoarchitectural derangement. One focal area of viable IM-HGD remained at the margin of one ablation zone (12 J/cm2, 2 applications) because of incomplete overlap. Complete ablation of IM-HGD without ablation of submucosa is possible using the HALO360 system. Ablation depth is dose related and limited to the muscularis mucosae. In one patient, small residual foci of IM-HGD at the edge of the ablation zone were attributable to incomplete overlap, which can be avoided. This study, together with nonesophagectomy IM-HGD trials currently underway, will identify the optimal treatment parameters for IM-HGD patients who would otherwise undergo esophagectomy or photodynamic therapy.Keywords
This publication has 37 references indexed in Scilit:
- Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon deviceSurgical Endoscopy, 2005
- Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trialGastrointestinal Endoscopy, 2005
- A Randomized, Multi-Center Evaluation of Ablation of Nondysplastic Short Segment Barrett Esophagus Using Barrx Bipolar Balloon Device: Extended Follow-Up of the Ablation of Intestinal Metaplasia (AIM)-I TrialGastrointestinal Endoscopy, 2005
- Successful Ablation of Barrett's Esophagus (BE) with Low Grade Dysplasia (LGD) Using Barrx Bipolar Balloon Device: Preliminary Results of the Ablation of Intestinal Metaplasia with LGD (AIM-LDG) TrialGastrointestinal Endoscopy, 2005
- Chronic symptoms after subtotal or partial oesophagectomy: diagnosis and treatmentBest Practice & Research Clinical Gastroenterology, 2004
- Photodynamic Therapy for Dysplastic Barrett's Esophagus and Mucosal AdenocarcinomaGastrointestinal Endoscopy, 2004
- Barrett's esophagusJournal of Gastrointestinal Surgery, 2004
- Photodynamic Therapy for Dysplastic Barrett Esophagus and Early Esophageal AdenocarcinomaMayo Clinic Proceedings, 2002
- Progression of Barretl's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's esophagus study) trialGastroenterology, 2001
- Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosisPublished by Elsevier ,2000